Graft Versus Host Disease therapies such as NIKTIMVO, JAKAVI/JAKAFI MOA, IMBRUVICA, RYONCIL/TEMCELL HS, and others are expected to boost the Graft Versus Host Disease Market in the upcoming years.
DelveInsight has launched a new report on “Graft Versus Host Disease – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Graft Versus Host Disease Market Report:
According to DelveInsight’s analysis, the GVHD Market in the 7MM was valued at approximately USD 1,301.8 million in 2023. It is projected to grow at a CAGR of 8.2% from 2025 to 2034.
Various therapies, including steroids, NIKTIMVO, JAKAVI/JAKAFI MOA, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, are available for managing GVHD.
GVHD-focused companies like CSL Behring, Equillium, MaaT Pharma, and REGiMMUNE are advancing their clinical trial assets, driving innovation and creating significant growth opportunities in the GVHD market.
DelveInsight estimates that in 2023, there were approximately 52 thousand GVHD cases in the 7MM. Of these, the United States accounted for 45%, EU4 and the UK represented 39%, and Japan had 16% of the cases.
In November 2024, Equillium expedited the timeline for completing EQ001 in the Phase III EQUATOR study for GVHD, aiming for completion by Q1 2025.
According to DelveInsight’s epidemiology model, there were approximately 57 thousand allogeneic transplant cases and nearly 52 thousand cases of Graft Versus Host Disease (GVHD) across the 7MM in 2023, with these numbers expected to rise by 2034.
In 2023, the US reported the highest number of GVHD cases among the 7MM, with around 24 thousand cases, a number expected to increase by 2034.
In the EU4 and the UK, Germany had the highest number of GVHD cases in 2023, reporting approximately 8 thousand cases, followed by Italy and France with around 3 thousand cases each. Spain had the lowest number, with approximately 2,700 cases.
Key Graft Versus Host Disease companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others are evaluating new drugs for Graft Versus Host Disease to improve the treatment landscape.
Key benefits of the Graft Versus Host Disease market report:
Graft Versus Host Disease market report covers a descriptive overview and comprehensive insight of the Graft Versus Host Disease Epidemiology and Graft Versus Host Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Graft Versus Host Disease market report provides insights on the current and emerging therapies.
Graft Versus Host Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Graft Versus Host Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft Versus Host Disease market.
Got queries? Click here to know more about the Graft Versus Host Disease Market Landscape.
Graft Versus Host Disease Overview
Graft Versus Host Disease (GVHD) is an immune disorder that occurs following transplant procedures when immune cells (T cells) from the donor (the graft) attack the tissues (healthy cells) of the recipient. This condition is a common side effect after an allogeneic bone marrow transplant and, in some cases, can be life-threatening. Prior to undergoing an allogeneic stem cell transplant, the patient typically receives high doses of chemotherapy or radiation to eliminate diseased cells and prepare the body for the donor cells.
GVHD primarily occurs in two forms: acute and chronic. A recipient of an allogeneic transplant may develop either type, both types, or none at all. On average, GVHD affects about 30-50% of patients who undergo allogeneic hematopoietic cell transplantation.
Graft Versus Host Disease Market Outlook
The dynamics of the Graft Versus Host Disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others during the forecast period 2020-2034.
Scope of the Graft Versus Host Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Graft Versus Host Disease Companies: Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others
Graft Versus Host Disease Therapeutic Assessment: Graft Versus Host Disease current marketed and Graft Versus Host Disease emerging therapies
Graft Versus Host Disease Market Dynamics: Graft Versus Host Disease market drivers and Graft Versus Host Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Graft Versus Host Disease Unmet Needs, KOL’s views, Analyst’s views, Graft Versus Host Disease Market Access and Reimbursement
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Graft Versus Host Disease Patient Share (%) Overview at a Glance
5. Graft Versus Host Disease Market Overview at a Glance
6. Graft Versus Host Disease Disease Background and Overview
7. Graft Versus Host Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft Versus Host Disease
9. Graft Versus Host Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Graft Versus Host Disease Emerging Therapies
12. Graft Versus Host Disease Market Outlook
13. Country-Wise Graft Versus Host Disease Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Graft Versus Host Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Graft Versus Host Disease Market Outlook 2034.
Related Reports:
Graft Versus Host Disease Pipeline Insights, DelveInsight
“Graft Versus Host Disease Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft Versus Host Disease market. A detailed picture of the Graft Versus Host Disease pipeline landscape is provided, which includes the disease overview and Graft Versus Host Disease treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
